Clinical Pharmacokinetics and Metabolism of Chloroquine
- 1 October 1996
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 31 (4) , 257-274
- https://doi.org/10.2165/00003088-199631040-00003
Abstract
This paper presents the current state of knowledge on chloroquine disposition, with special emphasis on stereoselectivity and microsomal metabolism. In addition, the impact of the patient’s physiopathological status and ethnic origin on chloroquine pharmacokinetics is discussed. In humans, chloroquine concentrations decline multiexponentially. The drug is extensively distributed, with a volume of distribution of 200 to 800 L/kg when calculated from plasma concentrations and 200 L/kg when estimated from whole blood data (concentrations being 5 to 10 times higher). Chloroquine is 60% bound to plasma proteins and equally cleared by the kidney and liver. Following administration chloroquine is rapidly dealkylated via cytochrome P450 enzymes (CYP) into the pharmacologically active desethylchloroquine and bisdesethylchloroquine. Desethylchloroquine and bisdesethylchloroquine concentrations reach 40 and 10% of chloroquine concentrations, respectively; both chloroquine and desethylchloroquine concentrations decline slowly, with elimination half-lives of 20 to 60 days. Both parent drug and metabolite can be detected in urine months after a single dose. In vitro and in vivo, chloroquine and desethylchloroquine competitively inhibit CYP2D1/6-mediated reactions. Limited in vitro studies and preliminary data from clinical experiments and observations point to CYP3A and CYP2D6 as the 2 major isoforms affected by or involved in chloroquine metabolism. In vitro efficacy studies did not detect any difference in potency between chloroquine enantiomers but, in vivo in rats, S(+)-chloroquine had a lower dose that elicited 50% of the maximal effect (ED950) than that of R(−)-chloroquine. Stereoselectivity in chloroquine body disposition could be responsible for this discrepancy. Chloroquine binding to plasma proteins is stereoselective, favouring S(+)-chloroquine (67% vs 35% for the R-enantiomer). Hence, unbound plasma concentrations are higher for R(−)-chloroquine. Following separate administration of the individual enantiomers, R(−)-chloroquine reached higher and more sustained blood concentrations. The shorter half-life of S(+)-chloroquine appears secondary to its faster clearance. Blood concentrations of the S(+)-forms of desethylchloroquine always exceeded those of the R(−)-forms, pointing to a preferential metabolism of S(+)-chloroquine.Keywords
This publication has 97 references indexed in Scilit:
- Drug Interaction of Chloroquine with CiclosporinNephron, 1992
- Pharmacokinetics of Chloroquine and Some of Its Metabolites in Healthy Volunteers: A Single Dose StudyThe Journal of Clinical Pharmacology, 1989
- Chloroqine Treatment of Severe Malaria in ChildrenNew England Journal of Medicine, 1988
- Placental and Milk Transfer of Chloroquine in HumansTherapeutic Drug Monitoring, 1988
- Chloroquine Elimination in Humans: Effect of Low‐Dose CimetidineThe Journal of Clinical Pharmacology, 1987
- Multiple-Drug Resistance in Human CancerNew England Journal of Medicine, 1987
- Parenteral Chloroquine for Treating Falciparum MalariaThe Journal of Infectious Diseases, 1987
- Clinical Pharmacokinetics of Antimalarial DrugsClinical Pharmacokinetics, 1985
- Complete heart block in chronic chloroquine poisoningInternational Journal of Cardiology, 1983
- Improved fluorimetrie assay of chloroquine in biological samplesJournal of Pharmacy and Pharmacology, 1980